Alzheimers disease, cognitive impairment
Conditions
Interventions
Experimental group:Receiving deep cervical lymphatic vein anastomosis Medication (donepezil 10mg/day, oral)
Control group:Receiving medical therapy (donepezil 10 mg/day orally) without surgery
Sponsors
Affiliated Hospital of Guangdong Medical University
Eligibility
Sex/Gender
All
Age
50 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. Age: 50 to 90 years old; 2. Clinically confirmed moderate to severe Alzheimer's disease, according to the 2024 NIA-AA diagnostic criteria; 3. Cognitive function assessment: MMSE score between 0 and 20; 4. Cerebrospinal fluid and blood tests confirm abnormalities in biomarkers (such as Aß and Tau protein) associated with Alzheimer's disease; 5. Patients or legal guardians who have signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Combined with other serious systemic underlying diseases, unable to tolerate general anesthesia, or have contraindications to surgery; 2. History of serious infection or infectious disease in the last 4 weeks; 3. Psychiatric disorders: including severe depression, schizophrenia and other diseases that may affect cognitive assessment; 4. Have recently participated in other clinical trials, which may affect the efficacy evaluation of this study; 5. Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement in cognitive function; | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement in quality of life;Changes in Aß and Tau protein levels in cerebrospinal fluid and blood;Improvement in cerebral lymphatic drainage function;Improvement in cognitive function;The incidence of postoperative complications; | — |
Countries
China
Contacts
Public ContactLi Zhenzhe
The Affiliated Hospital of Guangdong Medical University
Outcome results
None listed